Education
About Us
Working with TipRanks
Follow Us
NovoCure Ltd (NVCR)
NASDAQ:NVCR
Earnings Data
Report Date
Jul 24, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.38Last Year’s EPS
-0.31Same Quarter Last Year
Moderate Buy
Based on 6 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 24, 2025
|% Change Since: 9.00%
|Next Earnings Date:Jul 24, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted NovoCure Limited's successful expansion efforts with CE Mark approval in Europe and promising clinical trial results, which are overshadowed by financial losses and margin pressures. The company's strategic focus on expanding indications shows potential for growth, but current financial challenges are notable.Company Guidance
In NovoCure Limited's first quarter 2025 earnings call, several key metrics highlighted the company's momentum and strategic focus. The quarter saw a net revenue of $155 million, marking a 12% increase from the previous year, driven by a 40% patient growth in France and other regions. The company reported 92 prescriptions for non-small cell lung cancer, with 62 patients on therapy by the end of the quarter, alongside 44 mesothelioma patients, totaling 106 Optima active patients. NovoCure also celebrated the CE Mark approval for OptuneLua in Europe, positioning them for a launch in Germany. Additionally, the company managed to collect $1.5 million from OptuneLua claims, reflecting initial reimbursement efforts. Their adjusted EBITDA was negative $5 million, while they maintained a robust cash and investment balance of $929 million. Despite a quarterly net loss of $34 million, NovoCure remains focused on expanding its reach across multiple indications, leveraging its infrastructure for anticipated future growth and profitability.CE Mark Approval for OptuneLua
OptuneLua received European CE Mark approval for metastatic non-small cell lung cancer, allowing for concomitant treatment with immune checkpoint inhibitors or docetaxel. This approval opens up the European market, with Germany being launch-ready pending local registration.
Panova Three Clinical Trial Success
The Panova three phase three clinical trial in unresectable locally advanced pancreatic cancer demonstrated a meaningful survival benefit and was accepted for presentation at the ASCO annual meeting. This trial is the first and only phase three trial to show such a benefit in this cancer type.
Strong Financial Performance
NovoCure Limited reported $155 million in net revenue for Q1 2025, a 12% increase year-over-year. Active patients grew by 40% in France, 17% in Japan, 10% in Germany, and 4% in the US.
Non-Small Cell Lung Cancer Launch Success
The early commercial indicators for the US launch of OptuneLua for non-small cell lung cancer are promising, with 92 prescriptions and 62 patients on therapy in Q1 2025.
Expansion of Active Patient Base
The GBM segment showed strong performance with a record 4,162 active patients globally, highlighting continued growth especially in France and Japan.
NVCR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVCR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 24, 2025 | $17.77 | $18.55 | +4.39% |
Feb 27, 2025 | $21.96 | $19.23 | -12.43% |
Oct 30, 2024 | $16.89 | $16.99 | +0.59% |
Jul 25, 2024 | $18.79 | $18.65 | -0.75% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does NovoCure Ltd (NVCR) report earnings?
NovoCure Ltd (NVCR) is schdueled to report earning on Jul 24, 2025, TBA Not Confirmed.
What is NovoCure Ltd (NVCR) earnings time?
NovoCure Ltd (NVCR) earnings time is at Jul 24, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVCR EPS forecast?
NVCR EPS forecast for the fiscal quarter 2025 (Q2) is -0.38.